![]() ![]() Dosing was based on which fXa inhibitor they had been exposed to, and when. ![]() The primary site of bleeding was gastrointestinal 49% of patients, and intracranial in 42%.įor ethical reasons, the study was not randomised, and all patients received andexanet – first in an immediate bolus over 15-30 minutes, followed by a 2 hour infusion. The interim results include 67 patients, mean age 77 years, who required urgent reversal of acute major bleeding within 18 hours of receiving either a direct (apixaban, rivaroxaban, edoxaban) or indirect (enoxaparin) fXa inhibitor. Mark Crowther, ANNEXA-4 co-principal investigator, also from McMaster University. In these patients andexanet reduced the anticoagulant effect of the factor Xa inhibitors and was associated with effective haemostasis in most patients,” according to Dr. Although it has been shown to reduce anti-fXa activity in volunteers, until now we did not have experience in acutely bleeding patients. “Andexanet is the first specific agent designed for reversal of factor X inhibitors. The ANdexanet Alfa, a Novel Antidote to the Anticoagulation Effects of F XA Inhibitors (ANNEXA-4) study was presented at ESC Congress 2016, with simultaneous publication in The New England Journal of Medicine. Connolly, MD, from McMaster University, in Hamilton Ontario, Canada. Rome, Italy – 30 August, 2016: A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.Īndexanet alfa reduced anticoagulant activity by roughly 90% within half an hour among patients with acute major bleeding while receiving a factor Xa (fXa) inhibitor, resulting in “excellent or good” haemostasis at 12 hours in most subjects, reported lead investigator Stuart J. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |